Adipose-derived mesenchymal stem cells (AdMSCs) for the treatment of secondary progressive multiple sclerosis: A triple-blind, placebo-controlled, randomized phase I/II safety and feasibility study

Currently available treatments for secondary progressive multiple sclerosis (SPMS) have limited efficacy. Adipose-mesenchymal-derived stem cells (AdMSCs) represent a promising option and can be easily obtained with minimally invasive procedures.

In this placebo-controlled study, stem cell samples were harvested from consenting patients via lipectomy and subsequently expanded. Patients were given a single placebo, low-dose (1×106 cells/kg) or high-dose (4×106 cells/kg) infusion of autologous AdMSC product, and these patients were then monitored and followed for 12 months thereafter.

Thirty-four patients underwent lipectomy for collection of AdMSCs. They were then randomized and 30 were infused (11 with placebo, 10 with low dose, and 9 with high dose); 4 patients did not receive the infusion because of karyotype abnormalities in the cell product.

Only one contraindication emerged after infusion: urinary infection, considered, however, to be unrelated to the study at hand. No other “safety” parameters showed changes.

The study showed, therefore, that the infusion of autologous AdMSCs is safe and feasible in patients with SPMS. Larger studies in terms of number of participants and probably treatment at earlier stages of the disease would be needed to investigate the potential therapeutic benefit of this technique.

Musculoskeletal disorders and mesenchymal stem cells

Considered to be one of the leading causes of disability worldwide, musculoskeletal disorders include osteoarthritis, rheumatoid arthritis, low back pain, osteoporosis, sarcopenia and myofascial pain syndrome. There are several clinical studies investigating the efficacy of mesenchymal stem cells in these musculoskeletal disorders (MSDs).

The safety of MSC treatment in humans with osteoarthritis, a chronic inflammatory joint disease, was evaluated in a study of 12 patients. All patients had chronic knee pain. Treatment was performed by intra-articular injection of expanded autologous bone marrow mesenchymal stem cells (BM-MSC).

91% of the patients showed an improvement in cartilage quality.

Furthermore, in another clinical study, some patients were treated with an intra-articular injection of allogeneic BM-MSC (from a donor) and the same results were observed as an increase in cartilage quality. 

These results were undoubtedly obtained thanks to the potential of mesenchymal stem cells which, thanks to the microenvironment of the damaged site, expressed key genes in cartilage development and type II collagen synthesis promoting cartilage regeneration.

Stem cells: Did you know that there is great compatibility between siblings?

Stem cells are undifferentiated cells that are capable of forming the different cell types that make up an adult individual. Thanks to their ability to differentiate, stem cells are of great interest in various medical fields. Their greater histocompatibility is also interesting, so that this cell type can often be used within families. 

The probability of finding a compatible donor outside the family is 0.001 % (1 in 100,000 people). For siblings, on the other hand, the probability of a match is 25 % (1 in 4).

This means that the stem cells of your child that you have stored after birth are very likely to be compatible with the siblings.

Stem cell secretome from adipose tissue as a biotherapeutic agent to inhibit growth of triple-negative breast cancer 

n this experimental study, a protocol was developed for processing a formulation derived from secretome obtained from adipose tissue mesenchymal stem cells at different concentrations. Its molecular composition and in vitro efficacy was evaluated when applied to breast cancer cell lines. In addition, the ability of the formulation to suppress the growth of triple-negative breast cancer when infused into a mouse model of the disease was verified.

Continue reading

Outcomes of adipose tissue stem cell transplantation for the treatment of refractory lupus nephritis

To date, the immunomodulatory capacity of mesenchymal stem cells is well known. In this phase one clinical trial, the efficacy of these cells for the treatment of refractory lupus nephritis (LN) was verified. Specifically, 9 patients received systemic infusion of mesenchymal stem cells derived from adipose tissue and followed up for a 12-month follow-up period.

Continue reading

Outcomes of mesenchymal stem cell transplantation from umbilical cord for the treatment of decompensated liver cirrhosis

group (n = 111) and cord blood mesenchymal stem cell infusion group (n = 108). Both groups were followed up for a follow-up period of 7 years (October 2010 to October 2017). Specifically, patients in the control group received only conventional therapy while patients in the other group received three infusions of mesenchymal stem cells from cord tissue at four-week intervals.

Continue reading